TB-500: The Healing Peptide Under the Microscope
Last updated: March 2026
TB-500 is a synthetic fragment of thymosin beta-4 — a naturally occurring 43-amino acid peptide found in all human cells — studied across 544+ preclinical publications for tissue repair, wound healing, and anti-inflammatory effects. No completed human clinical trials exist for this specific fragment; only one company ever pursued human trials with thymosin beta-4, and only for eye drops.
on Thymosin Beta-4
Peptide Sequence
Human Uses
📋 On this page
- Four Key Mechanisms of Action
- Key Findings from Animal Studies
- The Human Evidence Gap
- TB-500 vs BPC-157
- Side Effects & Safety
- Additional Therapeutic Applications
- Regulatory Status
- Study Citations
- TB-500 vs Full Thymosin Beta-4: Does It Matter?
- Who Researches TB-500?
- 🎯 Who Is This For?
- Key Takeaways
- Related Resources
- Related Research Guides
- 🔗 Related Resources
- 🔬 Verified Research Source
Four Key Mechanisms of Action
Thymosin beta-4 is a multifunctional peptide that operates through several distinct biological pathways — all observed in preclinical models.
Binds monomeric G-actin to regulate cytoskeletal dynamics. This promotes cell migration — a critical step in wound healing and tissue repair. Tβ4 is the primary actin-sequestering peptide in mammalian cells.
Downregulates NF-κB signaling pathway, reducing production of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6. Observed across multiple tissue models including cardiac, dermal, and corneal tissue.
Promotes formation of new blood vessels in damaged tissue. Stimulates endothelial cell migration and tube formation — essential for delivering nutrients and oxygen to healing wounds.
Mobilizes cardiac and tissue progenitor cells via the Akt/PKB survival pathway. Activates integrin-linked kinase (ILK) to promote cell survival and migration in damaged heart tissue.
Key Findings from Animal Studies
The most-cited results from preclinical research. Important: these are all animal or in-vitro studies unless specifically noted.
All progress bars below represent animal study data. Results in mice and rats do not reliably predict human outcomes. These numbers show preclinical promise — not proven human efficacy.
The Human Evidence Gap
544+ studies sounds impressive. But when you look at what actually involved humans, the picture changes dramatically.
Human Trials
Patients Studied
Animal/In-Vitro
TB-500 vs BPC-157
Two of the most popular research peptides for healing — different mechanisms, different strengths, often stacked together.
- Systemic action — distributes throughout the body
- Better suited for deep tissue, tendon, and cardiac repair
- Promotes cell migration via actin sequestration
- Stronger angiogenesis response
- Subcutaneous injection only
- Banned by WADA since 2011
- More localized action — targets injury site
- Better for GI healing and localized injuries
- Derived from human gastric juice protein
- Stronger gut-brain axis effects
- Oral and injectable forms studied
- Also no FDA approval for human use
The "stack" is popular but unproven. Many in the peptide research community combine TB-500 and BPC-157. The rationale: complementary mechanisms (systemic + local). The evidence: zero human randomized controlled trials on the combination. It's theory, not science — yet.
Side Effects & Safety
What animal studies show — and what the community reports anecdotally. These are very different categories of evidence.
- Generally well-tolerated across multiple animal models
- No significant organ toxicity observed at standard doses
- No adverse effects on wound healing trajectory
- Cardioprotective at therapeutic doses in MI models
- Safe in corneal application (RegeneRx human pilot)
- Head rush / lightheadedness after injection
- Initial lethargy and fatigue (first few days)
- Injection site irritation and redness
- Temporary flu-like symptoms reported by some
- These are self-reports, not controlled observations
The cancer question: Thymosin beta-4 is upregulated in some cancer tissues. This has raised theoretical concerns. However, no causal evidence has been established — Tβ4 upregulation may be a response to tissue damage rather than a cause of abnormal growth. This remains an open question in the literature.
Additional Therapeutic Applications
Beyond musculoskeletal healing, thymosin beta-4 research has explored cardiovascular, neurological, and ophthalmic applications.
Tβ4 promotes wound healing with notably reduced scar tissue formation. Research shows it enhances collagen deposition while simultaneously reducing adhesions and fibrous bands — leading to more functional, less restricted healing compared to untreated wounds.
Animal studies demonstrate Tβ4's ability to promote regeneration of damaged cardiac tissue following myocardial infarction (heart attack). The Bock-Marquette 2004 study showed 50% scar reduction in mouse MI models — potentially through stem cell mobilization and anti-inflammatory pathways.
Preclinical studies have explored Tβ4 for traumatic brain injury (TBI) and spinal cord injury recovery. The peptide appears to support neuronal survival and may promote remyelination — though human data remains absent.
RegeneRx's RGN-259 — a topical ophthalmic formulation of Tβ4 — reached Phase 2/3 clinical trials for dry eye syndrome. This represents the only human clinical trial program for thymosin beta-4, showing the peptide's potential for corneal wound healing.
Cancer Concern Context: Elevated Tβ4 levels have been observed in certain cancer tissues, raising safety questions. However, current evidence suggests this is likely an immune response to tissue damage rather than tumor promotion. When tissue is damaged — whether by injury, inflammation, or cancer — the body upregulates healing factors like Tβ4. Correlation is not causation, but this remains an active research area.
Regulatory Status
TB-500 is not approved for human use anywhere in the world. Here's the full regulatory picture.
Not approved for human use. Investigational only. RegeneRx held an IND for ophthalmic Tβ4 (RGN-259) but no drug has been approved.
Investigational OnlyBanned by the World Anti-Doping Agency since 2011. Listed under S2 — Peptide Hormones, Growth Factors. Prohibited at all times, in and out of competition.
Banned Since 2011Banned in multiple jurisdictions. Several racehorses have tested positive for TB-500, leading to disqualifications and trainer suspensions.
Banned SubstanceAvailable from peptide suppliers labeled "for research use only." Not intended for human consumption. Quality and purity vary by supplier.
Research Use OnlyStudy Citations
The primary research behind the data on this page. Click PMID links to read the full papers on PubMed.
Fragment vs Full Peptide
TB-500 vs Full Thymosin Beta-4: Does It Matter?
TB-500 is a synthetic fragment — specifically the active region (amino acids 17-23) of the full 43-amino-acid thymosin beta-4 protein. This distinction matters more than most peptide guides acknowledge, and it's increasingly discussed among practitioners who work with both forms.
| Property | TB-500 (Fragment) | Full TB4 |
|---|---|---|
| Structure | Active region (aa 17-23) | Complete 43 amino acids |
| Actin Binding / Cell Migration | ✅ Primary mechanism | ✅ Included + additional domains |
| Angiogenesis | Partial | Full cascade |
| Inflammation Modulation | Moderate | Broader pathway coverage |
| Tissue Remodeling | Limited evidence | Collagen deposition + reduced scarring |
| Cardioprotection | Not demonstrated | Cardiac regeneration post-MI |
| Clinical Trials | Preclinical only | Phase 2 (dry eye, RegeneRx) |
| Availability | Widely available (research) | Less common, higher cost |
📋 Clinical Evidence: Full Thymosin Beta-4
The most advanced clinical work has been done with full TB4, not the fragment:
- RegeneRx Biopharmaceuticals advanced full TB4 through Phase 2 clinical trials for dry eye syndrome (topical ophthalmic formulation, brand name RGN-259). Results showed significant improvement in corneal staining scores and symptom relief vs placebo.
- Cardiac regeneration: Full TB4 demonstrated the ability to promote regeneration and remodeling of damaged cardiac tissue after myocardial infarction in preclinical models — reducing infarct size and improving functional recovery. These cardioprotective effects have not been demonstrated with the TB-500 fragment.
- Neuroprotection: Full TB4 showed benefits in traumatic brain injury and spinal cord injury models, promoting neural repair and reducing inflammation through mechanisms beyond just actin sequestration.
- Wound healing with reduced scarring: Full TB4 enhances collagen deposition while simultaneously reducing adhesions and fibrous band formation — a balance the fragment alone may not achieve as effectively. (Smart, et al., Ann NY Acad Sci, 2007)
⚖️ The Practical Bottom Line
TB-500 works. The preclinical evidence for the fragment's role in cell migration and tissue repair is solid. For many applications — particularly acute soft tissue injuries — the fragment delivers meaningful results and is more accessible.
Full TB4 may work better for complex or stubborn injuries. When you need the complete biological cascade — angiogenesis, anti-inflammatory modulation, tissue remodeling, and reduced scarring all working together — the full peptide engages more pathways. Practitioners who've used both frequently report that full TB4 produces deeper, more sustained healing responses, particularly in chronic injuries and when stacked with BPC-157 or GHK-Cu.
The tradeoff is availability and cost. Full TB4 is harder to source, more expensive, and less commonly carried by research suppliers. TB-500 remains the practical choice for most people, with the understanding that it's delivering a targeted signal rather than the complete one.
Self-Assessment
Who Researches TB-500?
This Research Is Commonly Explored By People Who...
- Are researching thymosin beta-4 fragments and their role in cell migration and tissue repair
- Have chronic soft tissue injuries and want to understand the preclinical evidence on healing acceleration
- Are interested in comparing TB-500 with BPC-157 for different types of tissue repair
- Want to understand the research on actin regulation and its role in wound healing
- Are exploring recovery-focused peptide research beyond conventional anti-inflammatories
This Research May Not Be Relevant If...
- You're looking for human clinical trial data — TB-500 research is primarily preclinical and animal-based
- You have active cancer or a history of malignancy — thymosin beta-4 has been studied in cell proliferation contexts
- You want a standalone recovery protocol — TB-500 research is typically studied alongside rehab and other interventions
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
🎯 Who Is This For?
✅ Good Candidate If You...
- • Have a soft tissue injury (muscle strain, ligament sprain) that's slow to heal
- • Deal with chronic inflammation from overtraining or repetitive motion
- • Are recovering from surgery and want to support tissue remodeling
- • Experience cardiac or vascular issues and are interested in thymosin beta-4 research
- • Have fibrosis or scarring you want to address through upregulated actin
❌ Not Ideal If You...
- • Are pregnant or breastfeeding — no human safety data
- • Have active cancer — TB-500 promotes cell migration and angiogenesis
- • Are looking for a muscle-building compound — TB-500 is a healing peptide, not anabolic
- • Have no active injury or inflammation — this is a recovery compound, not a general supplement
⚕️ Always consult a healthcare provider before starting any peptide protocol.
Key Takeaways
An honest assessment of where TB-500 research stands. The "don't know" column is intentionally longer.
- Tβ4 promotes cell migration and wound healing in animal models
- Anti-inflammatory effects are well-documented in preclinical research
- Cardiac scar reduction was significant in mice (50%)
- Tendon strength improved ~40% in rat models
- The peptide is well-tolerated in animal studies
- It's the primary actin-sequestering peptide in mammalian cells
- Whether any of this translates to humans (almost zero human data)
- Optimal dosing for any condition in humans
- Long-term safety profile in humans
- Whether the TB-500 + BPC-157 stack actually works (zero RCTs)
- If Tβ4 has any role in cancer promotion or progression
- Why only one company ever pursued human trials
- Whether injection site results translate to systemic benefits
- Purity and quality consistency from research suppliers
- Interaction effects with other medications
- Whether animal dose-response curves apply to humans at all
Related Research Guides
🔗 Related Resources
Research Supplies
Tools and supplies relevant to this research area.
As an Amazon Associate, HighPeptides earns from qualifying purchases.
Research-Grade TB-500
Research-grade TB-500 (thymosin beta-4) with COA. Studied for tissue repair and recovery.
Browse TB-500 at Swiss Chems →Affiliate link — supports HighPeptides at no extra cost.
This page is for educational and informational purposes only. It is not medical advice, and nothing here should be interpreted as a recommendation to use TB-500 or any peptide. TB-500 (Thymosin Beta-4) is NOT approved by the FDA for human use. It is a research compound available only for laboratory and investigational purposes. The studies cited are overwhelmingly preclinical (animal and in-vitro). Always consult a qualified healthcare provider before making any decisions about your health. HighPeptides does not sell peptides or endorse their use outside of legitimate research settings.
🔬 Verified Research Source
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports HighPeptides at no extra cost. All Swiss Chems products include third-party lab testing certificates.